Four-year follow-up from the ENCORE trial: A randomized, controlled, non-inferiority study comparing eliglustat to imiglucerase in patients with Gaucher disease type 1 stabilized on enzyme replacement therapy.

MLA

Cox, Timothy M., et al. “Four-Year Follow-up from the ENCORE Trial: A Randomized, Controlled, Non-Inferiority Study Comparing Eliglustat to Imiglucerase in Patients with Gaucher Disease Type 1 Stabilized on Enzyme Replacement Therapy.” Molecular Genetics & Metabolism, vol. 117, no. 2, Feb. 2016, p. S37. EBSCOhost, https://doi.org/10.1016/j.ymgme.2015.12.229.

APA

Cox, T. M., Drelichman, G., Balwani, M., Burrow, T. A., Lukina, E., Rosenbloom, B., Gaemers, S. J. M., Angell, J., & Judith Peterschmitt, M. (2016). Four-year follow-up from the ENCORE trial: A randomized, controlled, non-inferiority study comparing eliglustat to imiglucerase in patients with Gaucher disease type 1 stabilized on enzyme replacement therapy. Molecular Genetics & Metabolism, 117(2), S37. https://doi.org/10.1016/j.ymgme.2015.12.229

Chicago

Cox, Timothy M., Guillermo Drelichman, Manisha Balwani, Thomas Andrew Burrow, Elena Lukina, Barry Rosenbloom, Sebastiaan J.M. Gaemers, Jennifer Angell, and M. Judith Peterschmitt. 2016. “Four-Year Follow-up from the ENCORE Trial: A Randomized, Controlled, Non-Inferiority Study Comparing Eliglustat to Imiglucerase in Patients with Gaucher Disease Type 1 Stabilized on Enzyme Replacement Therapy.” Molecular Genetics & Metabolism 117 (2): S37. doi:10.1016/j.ymgme.2015.12.229.